{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:11:48Z","timestamp":1790806308350,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-61213-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:14:49Z","timestamp":1751382889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-941X","authenticated-orcid":false,"given":"Nan","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-9473","authenticated-orcid":false,"given":"Fang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-9871","authenticated-orcid":false,"given":"Qianshi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-3379","authenticated-orcid":false,"given":"Xinyu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-1328","authenticated-orcid":false,"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6000-8827","authenticated-orcid":false,"given":"Tony","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3344-674X","authenticated-orcid":false,"given":"Zheng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-235X","authenticated-orcid":false,"given":"Caigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"61213_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524\u2013541 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"61213_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"J Ross","year":"2009","unstructured":"Ross, J. et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.  oncologist 14, 320\u2013368 (2009).","journal-title":"oncologist"},{"key":"61213_CR3","first-page":"355","volume":"70","author":"G Choong","year":"2020","unstructured":"Choong, G., Cullen, G. & O\u2019Sullivan, C. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA: a cancer J. clinicians 70, 355\u2013374 (2020).","journal-title":"CA: a cancer J. clinicians"},{"key":"61213_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"S Swain","year":"2023","unstructured":"Swain, S., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"61213_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.  Lancet Oncol. 13, 25\u201332 (2012).","journal-title":"Lancet Oncol."},{"key":"61213_CR6","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss, A. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann. Oncol. 24, 2278\u20132284 (2013).","journal-title":"Ann. Oncol."},{"key":"61213_CR7","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin, M. et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.  Lancet Oncol. 18, 1688\u20131700 (2017).","journal-title":"Lancet Oncol."},{"key":"61213_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.  N. Engl. J. Med. 380, 617\u2013628 (2019).","journal-title":"N. Engl. J. Med."},{"key":"61213_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Dieras","year":"2017","unstructured":"Dieras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732\u2013742 (2017).","journal-title":"Lancet Oncol."},{"key":"61213_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"S Hurvitz","year":"2023","unstructured":"Hurvitz, S. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet (Lond., Engl.) 401, 105\u2013117 (2023).","journal-title":"Lancet (Lond., Engl.)"},{"key":"61213_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz, S. A. et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 19, 115\u2013126 (2018).","journal-title":"Lancet Oncol."},{"key":"61213_CR12","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"N Harbeck","year":"2017","unstructured":"Harbeck, N. et al. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)\u2013positive early breast cancer (BC): final analysis of the west german study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor\u2013positive phase ii randomized trial\u2014efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J. Clin. Oncol. 35, 3046\u20133054 (2017).","journal-title":"J. Clin. Oncol."},{"key":"61213_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/onc.2008.432","volume":"28","author":"M Scaltriti","year":"2009","unstructured":"Scaltriti, M. et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803\u2013814 (2009).","journal-title":"Oncogene"},{"key":"61213_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","volume":"4","author":"V Borges","year":"2018","unstructured":"Borges, V. et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2\/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 4, 1214\u20131220 (2018).","journal-title":"JAMA Oncol."},{"key":"61213_CR15","doi-asserted-by":"publisher","first-page":"OT-28-01","DOI":"10.1158\/1538-7445.SABCS20-OT-28-01","volume":"81","author":"S Hurvitz","year":"2021","unstructured":"Hurvitz, S. et al. Abstract OT-28-01: HER2CLIMB-02: a randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. Cancer Res. 81, OT-28-01\u2013OT-28-01 (2021).","journal-title":"Cancer Res."},{"key":"61213_CR16","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer. Clin. Cancer Res., 29, OF1-OF10 (2022).","DOI":"10.1158\/1078-0432.c.6532887"},{"key":"61213_CR17","doi-asserted-by":"crossref","unstructured":"Xichun, H. et al. ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Signal Transduct Target Ther 17, 56 (2025).","DOI":"10.1038\/s41392-025-02149-3"},{"key":"61213_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.  Lancet Oncol. 22, 351\u2013360 (2021).","journal-title":"Lancet Oncol."},{"key":"61213_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02708-3","volume":"20","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 20, 498 (2022).","journal-title":"BMC Med."},{"key":"61213_CR20","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 30, 1796\u20131804 (2012).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"61213_CR21","doi-asserted-by":"crossref","unstructured":"Debora, F. et al. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 3, 227\u2013234 (2017).","DOI":"10.1001\/jamaoncol.2016.3824"},{"key":"61213_CR22","doi-asserted-by":"crossref","unstructured":"Carey L. A. et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J. Clin. Oncol. 34, 542\u2013549 (2015).","DOI":"10.1200\/JCO.2015.62.1268"},{"key":"61213_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann. Oncol. 29, 646\u2013653 (2018).","journal-title":"Ann. Oncol."},{"key":"61213_CR24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst, M. S. et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 1630\u20131640 (2018).","journal-title":"Lancet Oncol."},{"key":"61213_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10549-018-05102-x","volume":"175","author":"H Rugo","year":"2019","unstructured":"Rugo, H. et al. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. Breast Cancer Res. Treat. 175, 5\u201315 (2019).","journal-title":"Breast Cancer Res. Treat."},{"key":"61213_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0140-6736(99)02374-0","volume":"353","author":"R Sainsbury","year":"1999","unstructured":"Sainsbury, R., Johnston, C. & Haward, B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet (Lond., Engl.) 353, 1132\u20131135 (1999).","journal-title":"Lancet (Lond., Engl.)"},{"key":"61213_CR27","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(99)02143-1","volume":"353","author":"M Richards","year":"1999","unstructured":"Richards, M., Westcombe, A., Love, S., Littlejohns, P. & Ramirez, A. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet (Lond., Engl.) 353, 1119\u20131126 (1999).","journal-title":"Lancet (Lond., Engl.)"},{"key":"61213_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jcjo.2021.02.028","volume":"57","author":"A Sharma","year":"2022","unstructured":"Sharma, A. et al. Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can. J. Ophthalmol. J. canadien d.\u2019ophtalmologie 57, 118\u2013126 (2022).","journal-title":"Can. J. Ophthalmol. J. canadien d.\u2019ophtalmologie"},{"key":"61213_CR29","unstructured":"MoBCEPoC. Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version. Zhonghua Bing Li Xue Za Zhi 49, 296\u2013304 (2020)."},{"key":"61213_CR30","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"W Symmans","year":"2007","unstructured":"Symmans, W. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 25, 4414\u20134422 (2007).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61213-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:14:51Z","timestamp":1751382891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61213-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61213"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61213-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZP is employee of Hengrui Pharmaceuticals. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6036"}}